Prime Medicine, Inc. (PRME) Tops Q3 EPS by 5c

Prime Medicine, Inc. (NASDAQ: PRME) reported Q3 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• AI/ML Innovations plans $2M private placement on the CSE